IRVINE, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary
health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin
care, sports nutrition, and pharmaceutical products, announced today it has been named to the 2016 OTCQX® Best 50, a ranking of top
performing companies traded on the OTCQX Best Market last year.
The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX market. The
ranking is calculated based on an equal weighting of one-year total return and average daily dollar volume growth in the previous
calendar year. Companies in the 2016 OTCQX Best 50 were ranked based on their performance in 2015.
For the complete 2016 OTCQX Best 50 ranking, visit the following link: http://www.otcmarkets.com/content/doc/2016-OTCQX-Best-50.pdf
The OTCQX Best Market offers the best informed and most efficient trading for established, investor-focused U.S. and
international companies. To qualify for OTCQX, companies must meet high financial standards, demonstrate compliance with U.S.
securities laws, be current in their disclosure and be sponsored by a professional third-party advisor. OTCQX companies are
distinguished by the excellence of their operations and diligence with which they convey their qualifications.
About ChromaDex
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary
ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to
our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as
"phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix
Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and
license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting
business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN®
nicotinamide riboside; pTeroPure®
pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; ProC3G®, a natural
black rice containing cyanidin-3-glucoside; IMMULINA™, a spirulina extract; and Purple Corn derived from a proprietary
non-GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. To learn more about ChromaDex, please
visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a
description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of
such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially
from those set forth in this release due to the risks and uncertainties inherent in ChromaDex's business. More detailed information
about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's
Annual Report on Form 10-K for the fiscal year ended January 3, 2015, ChromaDex's Quarter Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect
events or circumstances after the date hereof.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products
or ingredients are not intended to diagnose, treat, cure or prevent any disease.
ChromaDex Company Contact: Andrew Johnson, Director of Investor Relations 949-419-0288 andrewj@chromadex.com ChromaDex Investor Contacts: The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 bprag@delmarconsulting.com
